日本語フィールド
著者：*Masatsugu Hamaji, Atsushi Kawaguchi, Mitsugu Omasa, Tatsuo Nakagawa, Ryota Sumitomo, Cheng-Long Huang, Takuji Fujinaga, Masaki Ikeda, Tsuyoshi Shoji, Hiromichi Katakura, Hideki Motoyama, Toshi Menju, Akihiro Aoyama, Toshihiko Sato, Toyofumi Fengshi Chen-Yoshikawa, Makoto Sonobe, Hiroshi Date題名：Low incidence of and mortality from a second malignancy after resection of thymic carcinoma†発表情報：Interact Cardiovasc Thorac Surg 巻: 28 号: 3 ページ: 375-379キーワード：概要：Objectives: Previous studies have suggested that a second malignancy often develops after resection of thymoma; however, it remains unknown whether this is applicable to thymic carcinoma.
Methods: A retrospective chart review was performed based on our multi-institutional database of resected thymic epithelial tumours between 1991 and 2016. A second malignancy was defined as newly diagnosed after thymic tumour resection. The cumulative incidence of and related death from a second malignancy after thymic and neuroendocrine carcinoma resections were estimated using a competing risk model and were compared to those of patients undergoing a thymoma resection.
Results: Two hundred and thirty-eight patients were identified (thymic carcinoma 59; thymoma 179). A second malignancy developed in 1 patient (1.7%) with thymic carcinoma and in 17 patients (9.5%) with thymoma. Deaths from second malignancies were noted in 7 patients with thymoma. There was a tendency towards a lower cumulative incidence of and a lower cumulative death from a second malignancy after thymic carcinoma resection (P = 0.139 and P = 0.20, respectively) than after thymoma resection. The cumulative incidence of a second malignancy in patients with thymic carcinoma was 2.8% at 5 years and at 10 years (8.0% at 5 years and 11.8% at 10 years in patients with thymoma).
Conclusions: After resection of thymic and thymic neuroendocrine carcinoma, the probability of developing a second malignancy, as well as mortality from a second malignancy, is very low. A prospective study with a larger sample size is required to validate our results.抄録：英語フィールド
Author：*Masatsugu Hamaji, Atsushi Kawaguchi, Mitsugu Omasa, Tatsuo Nakagawa, Ryota Sumitomo, Cheng-Long Huang, Takuji Fujinaga, Masaki Ikeda, Tsuyoshi Shoji, Hiromichi Katakura, Hideki Motoyama, Toshi Menju, Akihiro Aoyama, Toshihiko Sato, Toyofumi Fengshi Chen-Yoshikawa, Makoto Sonobe, Hiroshi DateTitle：Low incidence of and mortality from a second malignancy after resection of thymic carcinoma†Announcement information:Interact Cardiovasc Thorac Surg Vol: 28 Issue: 3 Page: 375-379An abstract：Objectives: Previous studies have suggested that a second malignancy often develops after resection of thymoma; however, it remains unknown whether this is applicable to thymic carcinoma.
Methods: A retrospective chart review was performed based on our multi-institutional database of resected thymic epithelial tumours between 1991 and 2016. A second malignancy was defined as newly diagnosed after thymic tumour resection. The cumulative incidence of and related death from a second malignancy after thymic and neuroendocrine carcinoma resections were estimated using a competing risk model and were compared to those of patients undergoing a thymoma resection.
Results: Two hundred and thirty-eight patients were identified (thymic carcinoma 59; thymoma 179). A second malignancy developed in 1 patient (1.7%) with thymic carcinoma and in 17 patients (9.5%) with thymoma. Deaths from second malignancies were noted in 7 patients with thymoma. There was a tendency towards a lower cumulative incidence of and a lower cumulative death from a second malignancy after thymic carcinoma resection (P = 0.139 and P = 0.20, respectively) than after thymoma resection. The cumulative incidence of a second malignancy in patients with thymic carcinoma was 2.8% at 5 years and at 10 years (8.0% at 5 years and 11.8% at 10 years in patients with thymoma).
Conclusions: After resection of thymic and thymic neuroendocrine carcinoma, the probability of developing a second malignancy, as well as mortality from a second malignancy, is very low. A prospective study with a larger sample size is required to validate our results.